Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
View Patent ↗Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
1. A method of treating bacterial activity in the gastrointestinal tract of a subject, the method comprising:
orally administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of rifaximin δ together with a pharmaceutically acceptable excipient selected from the group consisting of diluting, binding, lubricating, disintegrating, colouring, flavouring and sweetening agents,
wherein rifaximin δ has a powder X-ray diffractogram showing peaks at values of the diffraction angles 2θ of about 5.7°±0.2, 6.7°±0.2, 7.1°±0.2, 8.0°±0.2, 8.7°±0.2, 10.4°±0.2, 10.8°±0.2, 11.3°±0.2, 12.1°±0.2, 17.0°±0.2, 17.3°±0.2, 17.5°±0.2, 18.5°±0.2, 18.8°±0.2, 19.1°±0.2, 21.0°±0.2, 21.5°±0.2.
2. The method of claim 1 , wherein the pharmaceutical composition is in a formulation selected from the group consisting of coated or uncoated tablet, hard or soft gelatin capsule, sugar-coated pill, lozenge, wafer sheet, pellet, and powder in sealed packet.
3. A method of treating bacterial activity in the gastrointestinal tract of a subject, the method comprising:
topically administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of rifaximin δ,
wherein rifaximin δ has a powder X-ray diffractogram showing peaks at values of the diffraction angles 2θ of about 5.7°±0.2, 6.7°±0.2, 7.1°±0.2, 8.0°±0.2, 8.7°±0.2, 10.4°±0.2, 10.8°±0.2, 11.3°±0.2, 12.1°±0.2, 17.0°±0.2, 17.3°±0.2, 17.5°±0.2, 18.5°±0.2, 18.8°±0.2, 19.1°±0.2, 21.0°±0.2, 21.5°±0.2.
4. The method of claim 3 , wherein the pharmaceutical composition is in a formulation selected from the group consisting of ointment, pomade, cream, gel and lotion.
5. The method of claim 1 , wherein rifaximin δ has a water content between 3.0% and 4.5%.
6. A method of treating bacterial activity in the gastrointestinal tract of a subject, the method comprising:
orally administering to the subject by oral route a pharmaceutical composition comprising a therapeutically effective amount of rifaximin ε together with a pharmaceutically acceptable excipient selected from the group consisting of diluting, binding, lubricating, disintegrating, colouring, flavouring and sweetening agents,
wherein rifaximin ε has a powder X-ray diffractogram showing peaks at values of the diffraction angles 2θ of 7.0°±0.2, 7.3°±0.2, 8.2°±0.2, 8.7°±0.2, 10.3°±0.2, 11.1°±0.2, 11.7°±0.2, 12.4°±0.2, 14.5°±0.2, 16.3°±0.2, 17.2°±0.2, 18.0°±0.2, 19.4°±0.2.
7. The method of claim 6 , wherein the pharmaceutical composition is in a formulation selected from the group consisting of coated or uncoated tablet, hard or soft gelatin capsule, sugar-coated pill, lozenge, wafer sheet, pellet, and powder in sealed packet.
8. A method of treating bacterial activity in the gastrointestinal tract of a subject, the method comprising:
topically administering to the subject by oral route a pharmaceutical composition comprising a therapeutically effective amount of rifaximin ε,
wherein rifaximin ε has a powder X-ray diffractogram showing peaks at values of the diffraction angles 2θ of 7.0°±0.2, 7.3°±0.2, 8.2°±0.2, 8.7°±0.2, 10.3°±0.2, 11.1°±0.2, 11.7°±0.2, 12.4°±0.2, 14.5°±0.2, 16.3°±0.2, 17.2°±0.2, 18.0°±0.2, 19.4°±0.2.
9. The method of claim 8 , wherein the pharmaceutical composition is in a formulation selected from the group consisting of ointment, pomade, cream, gel and lotion.